UIT Alternative Health Fund

Type of Fund: North American Equity Growth
Date Started: March 2017
Series A & F units of UIT Funds, a mutual fund trust
Eligible Plans: Eligible as an investment for RRSP's, RRIF's, RESP's, RDSP's & TFSA's

Fund Details
Series A RAM 420
Series F RAM 421
Management Fee 1.00%

Why Invest in this Fund:

We believe there is an investment opportunity in the alternative health area at a time when traditional healthcare has been challenged by government cost constraints and insurance limitations and more people are adopting new treatments and health regimens outside the traditional medical market to enhance health and wellness. Studies from medical journals like the Lancet, a well-known UK medical journal, show that alternative health treatments are increasing in adoption as people are dealing with nutritional issues. We believe that the federal government's plan to legalize the recreational cannabis market is a prime example of alternative health that represents a significant investment opportunity. As a result, we believe that Canadian Licensed Producers of medical cannabis are best positioned to benefit from these regulatory changes.

The UIT Alternative Health Fund Is Canada's first and only actively managed mutual fund that focuses in the cannabis sector. We believe that it's important to reduce risk by owning an actively managed portfolio that has the necessary liquidity and is able to take advantage of the changing dynamics in this early stage sector.

Key Drivers of Demand For Alternative Health:

- ✓ Healthcare coverage reductions leading people to seek alternatives
- ✓ Desire for preventative health and lifestyle choices
- ✓ Baby boomer generation desires quality active lifestyle
- ✓ Greater interest in a holistic approach to medicine
- ✓ Awareness of Cannabis as an alternative to traditional medicines

Canadian Medical Marijuana Patient Enrolment & Kgs Sold



Source: Health Canada

During December, several of Canada's largest pharmacy chains announced supply and distribution agreements with cannabis LP's. These arrangements include pharmacy chains obtaining licenses to cultivate and sell cannabis. This is a significant development in our opinion, with companies such as Shoppers Drug Mart (Aphria/MedReleaf) and PharamaChoice (Cannimed), joining McKesson's Canadian pharmacy brands Guardian/IDA (Maricann) that will be able to have doctors write prescriptions in the same way they would write prescriptions for other medicines can, in our opinion, lead to further adoption by medical practitioners, reducing the historical stigmas attached to medical cannabis and further legitimizing the sector.

We believe that the January 1st opening of the California legal adult use market is also legitimizing the sector. The state currently generates annual sales of $2 billion from the medical cannabis market that has been legal for two decades. California's legal adult-use cannabis market could have a larger impact on the global market than Canada's anticipated recreational market, as the state actually has more residents than Canada, and California is the most populous state in America, further adding to the sector's growth.

Other developments in the sector included a major two year agreement between Canada's Federal government and the provinces agreeing to split the tax revenues earned from cannabis sales, 75% for the provinces. With excise taxes anticipated to generate $400 million annually, this will provide significant benefits to the provinces, assisting them in the roll out of the legal recreational market.

We believe that the Canadian cannabis industry is witnessing significant growth as the July 2018 opening of the adult usage recreational market approaches. We believe that over the medium and longer term, those LP's that are growing profitably will provide investors with sound returns.